Active ingredientRitlecitinibCat. No. P-R069-001CAS 1792180-81-4Family · Pharmaceutical analytical standards
Ritlecitinib
An oral inhibitor of JAK3 and the TEC kinase family, approved in June 2023 in the United States and in September 2023 in the European Union for severe alopecia areata, in adults and adolescents aged 12 and over. This family brings together the active ingredient and other impurities.
Did you know?It binds covalently and irreversibly to a cysteine at position 909 of JAK3; the TEC family kinases have the same cysteine at the equivalent position, which is why it blocks both.
Go to the active ingredient →Active ingredientRitlecitinibCat. No. P-R069-001CAS 1792180-81-4
ImpurityRitlecitinib Dimer ImpurityCat. No. P-R069-002CAS 2374827-88-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.